搜尋結果
About CDC. CDC is the nation's leading science-based, data-driven, service organization that protects the public's health. CDC works 24/7 to protect America from health, safety and security threats, both foreign and in the U.S. About CDC. Organization and Mission.
2024年4月25日 · There are safe and effective ways to recover from SUDs. Finding the right treatment option can be the key to a successful recovery journey. Outpatient counseling. Helps people understand addiction, their triggers, and their reasons for using drugs.
2024年4月2日 · Learn about lifesaving naloxone. Understand the risks of polysubstance use. Reduce stigma around recovery and treatment. Answers to frequently asked questions about reversing an opioid overdose with naloxone.
- Overview
- Risk Factors for Severe COVID-19
- Outpatient Treatments for COVID-19
•There is strong scientific evidence that antiviral treatment of persons with mild to moderate illness who are at risk for severe COVID-19 reduces their risk of hospitalization and death.
•The antiviral drugs ritonavir-boosted nirmatrelvir (Paxlovid) and remdesivir (Veklury) are the preferred treatments for eligible adult and pediatric patients who are at high risk for progression to severe COVID-19.
Clinicians can use the links below to identify patients at risk for severe COVID-19 and who may benefit from outpatient treatment. Severe outcomes of COVID-19 are defined as hospitalization, intensive care, ventilatory support, or death. There may be other medical conditions associated with severe COVID-19 not listed here, and clinical judgment is needed to accurately assess a person’s risk.
Age is the most important risk factor for severe outcomes of COVID-19. Risk factors for severe COVID-19 include:
•Age over 50 years, with risk increasing substantially at age ≥ 65 years
•Being unvaccinated or not being up to date on COVID-19 vaccinations
•Specific medical conditions, including immunocompromising conditions
Some racial and ethnic minority groups are disproportionately affected by COVID-19 because of many factors, including limited access to vaccines and healthcare.(1-3) Healthcare providers can consider these factors when evaluating the risk for severe COVID-19 and use of therapeutics.
Oral ritonavir-boosted nirmatrelvir (Paxlovid)
In a clinical trial, ritonavir-boosted nirmatrelvir reduced the risk of hospitalization and death by 86% in unvaccinated outpatients with COVID-19 at higher risk of severe disease. Serious adverse events are uncommon with Paxlovid treatment.(4) Similar results were observed in patients with prior immunity to the virus that causes COVID-19. Among patients in the EPIC-HR trial who were antibody positive at trial enrollment, the risk of COVID-19-related hospitalization or death from any cause during 28 days of follow-up was 0.2% among those treated with ritonavir-boosted nirmatrelvir compared with 1.7% of those receiving placebo. Ritonavir-boosted nirmatrelvir is given twice daily for 5 days, starting as soon as possible and within 5 days of symptom onset, and is approved for use in adults and authorized for use in pediatric patients (12 years of age and older weighing at least 40kg). Clinicians may recommend longer or additional courses of ritonavir-boosted nirmatrelvir for immunocompromised patients who continue experiencing COVID-19 symptoms after receiving antiviral treatment. Clinicians should be aware of the eligibility criteria and the potential for drug interactions with the use of ritonavir-boosted nirmatrelvir that may preclude ritonavir-boosted nirmatrelvir use or may require temporary discontinuation of other medications.
Symptomatic Management
All patients with symptomatic COVID-19 should be offered symptom management with over-the-counter antipyretics, analgesics, or antitussives for fever, headache, myalgias, and cough.(7)
More Information
For Healthcare Providers •Clinical Decision Aid for COVID-19 Outpatient Therapeutics •Side-by-Side Overview of Outpatient Therapeutics •NIH Treatment Guidelines for Non-Hospitalized Adults •FDA List of Current COVID-19 Emergency Use Authorization Products •Outpatient COVID-19 Therapeutics Administration Guide •COVID-19 Therapeutics Locator •Clinical Considerations for Children and Adults with Confirmed COVID-19 •FDA Approval for Remdesivir •Prescribing Information for Remdesivir •Emergency Use Authorization (EUA) of COVID-19 convalescent plasma for treatment of Coronavirus Disease 2019 (COVID-19) •NIH COVID-19 Treatment Guidelines: COVID-19 Convalescent Plasma •COVID-19 Therapeutics Commercialization Transition Guide | October 20, 2023 (hhs.gov) For Patients •Coronavirus (COVID-19) Drugs •What are Oral Antivirals? •COVID-19 Test to Treat Locator •COVID-19 Test to Treat Fact Sheet
2024年5月15日 · Overview. If someone you know shows signs of stroke, call 9-1-1 right away. Your stroke treatment begins the moment emergency medical services (EMS) arrive to take you to the hospital. Once at the hospital, you may receive emergency care, treatment to prevent another stroke, rehabilitation to treat the side effects of stroke, and/or all three.
2023年12月21日 · With COVID-19 hospitalizations on the rise, it is important that people who get sick and are at higher risk for severe illness get on treatment in the first days of illness because symptoms can change and worsen quickly. While these antivirals are effective at preventing severe disease, not enough people are taking them.
2024年4月9日 · CDC’s Respiratory Virus Guidance provides actions you can take to help protect yourself and others from health risks caused by respiratory viruses, including COVID-19. These actions include steps you can take to lower the risk of COVID-19 transmission (catching and spreading COVID-19) and lower the risk of severe illness if you get sick.
